ASH 2021 – Bluebird looks to revive Lentiglobin

Bluebird Bio has had a rough 2021, with cancer scares for two of its projects and the withdrawal of Lentiglobin in Europe. But the group will be hoping to put its annus horribilis behind it with promising Lentiglobin data in sickle cell disease, presented at Ash today.

Still, Bluebird does not expect a US filing in sickle cell until the first quarter of 2023, it recently disclosed. By this time it is likely to have been overtaken by Crispr and Vertex, which plan to submit their gene edited sickle cell candidate CTX001 late next year.